Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

{
  "signal_id": "80cdbb2e-6f6d-3231-2598-4bed1957ed3b",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-10-29T10:45:00+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/lilly-reports-third-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-regulatory-progress-across-the-portfolio-302922907.html",
    "title": "Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio",
    "ticker": "NYSE:LLY",
    "excerpt": "INDIANAPOLIS , Oct. 29, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the third quarter of 2026 and provided updated 2026 financial guidance. \"Lilly had another strong quarter, exceeding our prior expectations and allowing us to raise our full-year outlook,\" said David A. Ricks, Lilly chair and CEO. \"Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience. To drive durable long-term growth, we continue to invest in our drug-making and technology capabilities, with multiple business development deals and partnerships signed and closed, and with new manufacturing expansions in Texas and Virginia. Lilly is executing well across the value chain, and our potential for impact on human health continues to expand.\" Financial Results $ in millions, except per share data Third-Quarter 2026 2025 % Change Revenue $ 24,397 $ 17,601 39 % Net income – Reported 6,451 5,583 16 % Earnings per share – Reported (1) 7.22 6.21 16 % Net income – Non-GAAP 6,679 6,312 6 % Earnings per share – Non-GAAP (1) 7.48 7.02 7 % (1) Q3 2026 reported and non-GAAP EPS included $4.57 of acquired IPR&D charges compared to $0.71 in Q3 2025 A discussion of the non-GAAP financial measures...",
    "summary": "Eli Lilly and Company reported third-quarter 2026 net income of $6.5 billion.",
    "location": "Indianapolis, Indiana, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS270365/ELI-LILLY-AND-COMPANY-LOGO.jpg?id=OA3045659&p=facebook",
    "confidence": 0.95,
    "published_at": "2026-10-29T10:45:00Z",
    "location_data": [
      {
        "city": "Indianapolis",
        "state": "Indiana",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "In Q3 2026, net income and earnings per share (EPS) were $6.5 billion and $7.22, respectively, compared with net income of $5.6 billion and EPS of $6.21 in Q3 2025.",
    "amount_normalized": 6500000000
  }
}

curl https://signals.autobound.ai/v1/signals/80cdbb2e-6f6d-3231-2598-4bed1957ed3b \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"lilly.com","limit":20}'